NASDAQ · NVCR
Healthcare · Medical - Instruments & Supplies
$14.61
Up+$1.18 (+8.79%)
Updated Nov 5, 2026, 2:24 AM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · NVCR
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
NVCR closed at $14.61 after 21 trading sessions, down 0.34% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $14.00 | $14.94 | $13.915 | $14.61 | 1.65M |
| Nov 3, 2026 | $13.30 | $13.555 | $13.21 | $13.43 | 1.65M |
| Nov 2, 2026 | $13.33 | $13.67 | $13.08 | $13.21 | 1.65M |
| Oct 30, 2026 | $12.81 | $13.26 | $12.515 | $13.15 | 1.97M |
| Oct 29, 2026 | $12.605 | $13.85 | $11.85 | $13.11 | 5.96M |
| Oct 28, 2026 | $14.44 | $14.64 | $13.845 | $14.17 | 2.39M |
| Oct 27, 2026 | $14.49 | $14.74 | $14.11 | $14.62 | 2.47M |
| Oct 26, 2026 | $14.47 | $14.895 | $14.20 | $14.40 | 1.17M |
| Oct 23, 2026 | $14.85 | $14.97 | $14.53 | $14.68 | 1.13M |
| Oct 22, 2026 | $15.55 | $15.655 | $14.935 | $15.10 | 1.06M |
| Oct 21, 2026 | $15.60 | $16.0942 | $15.43 | $15.59 | 2.6M |
| Oct 20, 2026 | $14.98 | $15.82 | $14.905 | $15.71 | 1.74M |
| Oct 19, 2026 | $14.14 | $15.00 | $14.14 | $14.89 | 2.23M |
| Oct 16, 2026 | $14.41 | $14.41 | $13.875 | $14.07 | 1.29M |
| Oct 15, 2026 | $13.85 | $14.46 | $13.835 | $14.41 | 1.81M |
| Oct 14, 2026 | $14.15 | $14.26 | $13.76 | $13.84 | 1.19M |
| Oct 13, 2026 | $14.66 | $14.75 | $14.29 | $14.30 | 772.63K |
| Oct 12, 2026 | $14.54 | $14.76 | $14.26 | $14.72 | 781.98K |
| Oct 9, 2026 | $14.17 | $14.78 | $14.14 | $14.58 | 1.02M |
| Oct 8, 2026 | $14.59 | $14.59 | $13.8207 | $14.22 | 2.96M |
| Oct 7, 2026 | $14.84 | $15.12 | $14.59 | $14.66 | 3.51M |
The latest Smart Investors Daily articles mentioning NVCR.
Company
Market Activity
Research & News
NVCR research
Filterable reporting and market headlines.
Filters are reflected in the page URL for sharing and back-button support.
5 matching articles.
Yahoo · Nov 2, 2026
Explore how NovoCure's (NVCR) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
SeekingAlpha · Oct 31, 2026
2026-10-31. The following slide deck was published by NovoCure Limited in conjunction with their 2026 Q3 earnings call.
Benzinga · Oct 30, 2026
Wells Fargo analyst Larry Biegelsen maintains NovoCure (NASDAQ:NVCR) with a Equal-Weight and lowers the price target from $20 to $15.
Yahoo · Nov 2, 2026
Japan's emergence as a second major market is offsetting headwinds in pancreatic cancer, testing whether geographic diversification can sustain growth.
Yahoo · Oct 31, 2026
NovoCure came into this Q3 2026 report with a bruised chart, down double digits over the past month, yet the stock barely moved today, up just 0.3% around US$13. That muted reaction sits awkwardly against a quarter that delivered record net revenue of US$193.4m and the strongest profitability profile NovoCure has shown in recent periods, with adjusted EBITDA swinging into positive territory. Right now the market is treating this as a non-event. The numbers suggest a sentiment mismatch built...
The latest Smart Investors Daily articles mentioning NVCR.
